RegenETP (BST:NJT) - Stock Price, News & Analysis

NJT Stock Overview

A clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. More details

NJT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Earnings have grown 34.6% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (€177K)

Makes less than USD$1m in revenue ($73K)

Shares are highly illiquid

Has less than 1 year of cash runway

+ 1 more risk

RegenETP, Inc. Competitors

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Sangui Biotech International

HMSE:SBH

€419.8k

Paion

DB:PA8K

€42.8k

Epigenomics

DB:ECX

€1.2m

Price History & Performance

Summary of all time highs, changes and price drops for RegenETP
Historical stock prices
Current Share Price	US$0.036
52 Week High	US$0.07
52 Week Low	US$0.035
Beta	0.91
11 Month Change	0%
3 Month Change	0.56%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-59.55%

Recent updates

Shareholder Returns

	NJT	DE Biotechs	DE Market
7D	0%	-1.1%	1.1%
1Y	n/a	-18.8%	7.2%

Return vs Industry: Insufficient data to determine how NJT performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how NJT performed against the German Market.

Price Volatility

Is NJT's price volatile compared to industry and market?
NJT volatility
NJT Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: NJT has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine NJT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	43	Richard Hague	www.polarityte.com

RegenETP, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services.

RegenETP, Inc. Fundamentals Summary

How do RegenETP's earnings and revenue compare to its market cap?
NJT fundamental statistics
Market cap	€162.82k
Earnings (TTM)	-€7.64m
Revenue (TTM)	€67.17k

2.4x

P/S Ratio

0.0x

P/E Ratio

Is NJT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NJT income statement (TTM)
Revenue	US$73.00k
Cost of Revenue	US$125.00k
Gross Profit	-US$52.00k
Other Expenses	US$8.25m
Earnings	-US$8.30m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-1.15
Gross Margin	-71.23%
Net Profit Margin	-11,376.71%
Debt/Equity Ratio	0%

How did NJT perform over the long term?

See historical performance and comparison

RegenETP BST:NJT Stock Report